1258226-87-7|Ombitasvir|Ombitasvir|MFCD28386270-范德生物科技公司

Ombitasvir

NMR下载 COA and HPLC MSDS下载
names：
Ombitasvir
CAS号：
1258226-87-7
MDL Number： MFCD28386270
MF(分子式)： C50H67N7O8 MW(分子量)： 894.11
EINECS: Reaxys Number:
Pubchem ID:54767916 Brand:BIOFOUNT

Ombitasvir(1258226-87-7)是吡咯烷，氨基甲酸酯，芳族酰胺和二肽的成员。Ombitasvir结合并阻断NS5A蛋白的活性。这导致病毒RNA复制复合物的破坏，HCV RNA产生的阻断和病毒复制的抑制。 NS5A是一种与锌结合且富含脯氨酸的亲水性磷蛋白，在HCV RNA复制中起关键作用。 HCV是属于黄病毒科的小型带包膜单链RNA病毒；

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000558-10mg	10mg	99.79%	¥ 1822.00	¥ 1822.00		2-3天	- +	¥ 0.00
YZM000558-5mg	5mg	99.79%	¥ 1072.50	¥ 1072.50		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Ombitasvir(cas:1258226-87-7),ABT-267,ABT267,ABT 267
英文别名	Ombitasvir(cas:1258226-87-7),ABT-267,ABT267,ABT 267,Ombitasvir(ABT-267)
CAS号	1258226-87-7
SMILES	CC(C)(C)C(C=C1)=CC=C1N2[C@H](C3=CC=C(NC([C@H]4N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC4)=O)C=C3)CC[C@H]2C5=CC=C(NC([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)=O)C=C5
Inchi	InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
InchiKey	PIDFDZJZLOTZTM-KHVQSSSXSA-N
分子式 Formula	C50H67N7O8
分子量 Molecular Weight	894.11
闪点 FP	598.2±34.3 °C
熔点 Melting point	No data available
沸点 Boiling point	1065.6±65.0 °C at 760 mmHg
Polarizability极化度	98.3±0.5 10-24cm3
密度 Density	1.2±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±0.3 mmHg at 25°C
溶解度Solubility	生物体外In Vitro:DMSO溶解度≥ 33 mg/mL(36.91 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状	固体粉末,Power
储藏条件 Storage conditions	-20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

Ombitasvir(CAS:1258226-87-7)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:Ombitasvir蒸汽压,Ombitasvir合成,Ombitasvir标准,Ombitasvir应用,Ombitasvir合成,Ombitasvir沸点,Ombitasvir闪点,Ombitasvir用途,Ombitasvir溶解度,Ombitasvir价格,Ombitasvir作用,Ombitasvir结构式,Ombitasvir用处

产品说明	Ombitasvir(1258226-87-7) 是一种有效的HCV NS5A的抑制剂,Ombitasvir溶解度,OmbitasvirMSDS详见主页
Introduction	Ombitasvir(1258226-87-7) is a potent inhibitor of thehepatitis C virus protein NS5A。
Application1	Ombitasvir(1258226-87-7) is a potent inhibitor of thehepatitis C virus protein NS5A，withEC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
Application2
Application3

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

2017-07-01 Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use Drugs

2016-08-01 Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans Drug metabolism and disposition: the biological fate of chemicals

2016-08-01 Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection Drugs

2015-09-01 Interferon-free therapy for hepatitis C: The hurdles amid a golden era Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association

2015-05-01 Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection The Annals of pharmacotherapy

1.Clinical Pharmacokinetics of Ombitasvir Clinical Pharmacokinetics 2017
Abstract：Ombitasvir is a potent, nonstructural protein 5A inhibitor of the hepatitis C virus (HCV) that is used in combination with other direct-acting antivirals for the treatment of chronic HCV infection. Ombitasvir is predominantly metabolized by amide hydrolysis followed by oxidative metabolism and is a substrate of P-glycoprotein. Ombitasvir displays linear pharmacokinetics with minimal accumulation and is eliminated via metabolism and biliary excretion. A negligible amount of unchanged drug is excreted in urine. Exposures are comparable across Chinese, Japanese, and non-Asian subjects. The pharmacokinetic characteristics of ombitasvir are similar in healthy subjects and HCV-infected patients, and are not appreciably altered by hepatic or renal impairment. Results from several drug interaction studies demonstrated that ombitasvir has a low potential for drug interactions.
2.Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection Drugs 2016
Abstract：A fixed-dose tablet comprising the NS5A inhibitor ombitasvir, the NS3/4A inhibitor paritaprevir and ritonavir (ombitasvir/paritaprevir/ritonavir) (Technivie®, Viekirax®) is available for use, in combination with ribavirin, for the treatment of chronic hepatitis C virus (HCV) genotype 4 infection. High sustained virological response rates at 12 weeks post-treatment (SVR12) were achieved in treatment-naive or -experienced patients with chronic HCV genotype 4 infection, including patients without cirrhosis who received ombitasvir plus paritaprevir and ritonavir in combination with ribavirin for 12 weeks (SVR12 100 %) (PEARL-I trial), patients with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 or 16 weeks (SVR12 97 and 98 %) (AGATE-I trial) , or Egyptian patients without cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 weeks (SVR12 94 %) or with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plu s ribavirin for 12 or 24 weeks (SVR12 97 and 93 %) (AGATE-II trial). Ombitasvir/paritaprevir/ritonavir was generally well tolerated in patients with chronic HCV genotype 4 infection without cirrhosis or with compensated cirrhosis in clinical trials. There have been postmarketing reports of hepatic decompensation and hepatic failure, which mainly occurred in patients with advanced cirrhosis who received regimens containing ombitasvir/paritaprevir/ritonavir. In conclusion, ombitasvir/paritaprevir/ritonavir is a valuable option for use in patients with chronic HCV genotype 4 infection without cirrhosis or with compensated cirrhosis.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开